Piascledine 300Mg 30'S

PIASCLEDINE 300MG 30'S

Piascledine that is derived from avocado and soy,is an intriguing supplement on the market in Europe. The supplement concentrates the active ingredient considered crucial for the control of arthritic pain.

This supplement has been tested in placebo-controlled trials in France by the company that makes it.

The Cochrane Collaboration, an independent science group, has evaluated these studies.

Basically, Piascledine has "moderate to high" evidence that it works in the short-term to relieve the pain. This is good news as this is a natural product with little to no side effect profile.

A more long-term study (three years) found little difference in pain control between the supplement and placebo.

A review study in 2008 found that the use of the avocado-soybean oil supplement reduced and even stopped the need to use NSAIDs (anti-inflammatory pills). The product is derived from the unsaponifiable part of the oil of the vegetable.

This is a tiny fraction of the overall mass of the soybean and the avocado.

The amount of avocados and soybeans that would need to be consumed to equal the unsaponifiable dose in the supplement is too large to recommend a dietary source for this substance.

This product is another natural remedy with a good side effect profile that has been found to be an effective way to treat the pain of arthritis.

You should check with your doctor to make sure it will not interfere with any current supplements of medications prior to trying this product.

The avocado combination provides anti-inflammatory activity and also has been shown to actually build up cartilage in the laboratory.

The product is an unsaponifiable. The unsaponifiable and anti-inflammatory product has shown a decrease in destruction of the joints over time. This has been examined at the University of Arizona.

To investigate that a 6-month treatment with avocado soybean unsaponifiable (Piascledine 300 mg) once daily isas effective aswith chondroitin sulfate 400 mg three times daily in femorotibial gonarthrosis, and also the carry-over effect for two more months is comparable